Problem Cases of Rosacea - PowerPoint PPT Presentation

1 / 36
About This Presentation
Title:

Problem Cases of Rosacea

Description:

Anti-inflammatory dose doxycycline. Flushing. Beta blockers. Clonidine ... Pharmacokinetics: Anti-inflammatory dose doxycycline *16 healthy adult subjects ... – PowerPoint PPT presentation

Number of Views:485
Avg rating:3.0/5.0
Slides: 37
Provided by: gtau4
Category:

less

Transcript and Presenter's Notes

Title: Problem Cases of Rosacea


1
Problem Cases of Rosacea
AAD 20 min
  • Diane M. Thiboutot, M.D.
  • Professor of Dermatology
  • The Pennsylvania State University
  • College of Medicine
  • Hershey, PA

2
Disclosure
  • Clinical trials investigator and consultant
  • Galderma
  • Intendis

3
Why is rosacea so hard to manage?
  • Diagnostic challenge
  • Acne, perioral dermatitis, seb derm, SLE,
    photodamage
  • Childhood rosacea?
  • Varied appearance
  • Different subtypes
  • Varying skin types
  • Limited understanding of pathophysiology
  • Effective therapies against some but not all
    features of the disease

4
Rosacea Etiology
  • Unknown, controversial aspects
  • Genetics
  • Helicobacter pylori
  • Demodex folliculorum
  • Oxygen free radicals
  • P. acnes?
  • Bacterial antigens (Bacillus oleronius)
  • Increased activity of kallikrein 5
  • Photodamage/ new vessel formation

5
Altered innate immune defense in rosacea skin
  • Rosacea patients have increased cathelicidin
    expression
  • Increased levels of pro-inflammatory LL-37 and
    unique peptides vs. normals
  • Increased activity of kallikrein 5 (SCTE) that
    processes the pro-cathelicidin
  • In mice, injection of peptides, SCTE increases
    skin inflammation

Yamasaki K et al. Nature Medicine 13 975-980,
2007
6
Proteolytic processing of peptides
Bevins et al. Nature Med 13904,2007
  • Normal Rosacea
  • Cathelicidin precursor Cathelicidin precursor

SCTE (Klk5)
SCTE (Klk5)
LL-37 and variant peptides
LL-37
Angiogenic
Proinflammatory activities
Chemotactic
Bactericidal
7
Photodamage and new vessel formation
  • Endothelial cells placed in a matrix of damaged
    collagen will form tubular structures
  • These data suggest that damage to collagen (such
    as photodamage in rosacea) can induce new vessel
    formation (telangiectasia)

Varani, Perone, Warner, Dame, Kang, Fisher,
Voorhees. Br J Cancer 98 1646-1652, 2008
8
Clinical Presentations of Rosaca
9
Therapeutic Options in Rosacea
10
Oral Therapies
11
Oral Therapies
  • Inflammatory lesions, ocular rosacea
  • Tetracyclines
  • Minocycline, doxycycline
  • Metronidazole
  • Anti-inflammatory dose doxycycline
  • Flushing
  • Beta blockers
  • Clonidine
  • Extreme or recalcitrant cases
  • Isotretinoin (variable duration of effect)

12
Anti-inflammatory mechanisms of tetracyclines
  • Downregulate proinflammatory cytokines and
    metabolites of arachidonic acid
  • Inhibit angiogenesis, reactive oxygen species,
    neutrophil chemotaxis and matrix
    metalloproteinases (tissue remodeling)

13
Pharmacokinetics Anti-inflammatory dose
doxycycline
16 healthy adult subjects per arm mean weight
75 kg Measured at 7 days
Data on file, CollaGenex Pharmaceuticals, Inc.
14
Isotretinoin and rosacea
  • Has been used
  • Results are often not long-lasting
  • Beneficial in rosacea varients

15
Topical therapies
16
Topical Agents
  • Primary1
  • Metronidazole
  • Azelaic acid
  • Sodium sulfacetamide and sulfur
  • Secondary
  • Clindamycin
  • Erythromycin
  • Benzoyl peroxide
  • Other agents (e.g., tretinoin, tacrolimus,
    pimecrolimus) have been used

Not approved for the treatment of rosacea
1. Nally JB, Berson DS. J Drugs Dermatol.
20065(1)23-26.
17
Metronidazole Gel 1 Phase III Study Reduction
in Inflammatory Lesions
p.0001 vs. Vehicle
Median Reduction
10 weeks
Data on File Study Report 0215-R5.C-01-02
18
Azelaic Acid (Finacea) Percent Change in
Inflammatory Lesion Count
Weeks
Thiboutot D et al. J Am Acad Dermatol.
200348836-845.
19
Physical Therapies
20
Therapies for Erythema/Telangiectasia
  • Oral and topical medications are ineffective
  • Laser/light therapies

21
Light Sources in Rosacea
  • Monochromatic
  • KTP 532 nm
  • PDL 585-595 nm
  • CO2 10,600 nm
  • Polychromatic
  • IPL 515-1200 nm
  • Rosacea features
  • Telangiectasia, erythema
  • Telangiectasia, erythema
  • Phymas
  • Telangiectasia, erythema

22
Therapies for Rhinophyma
  • Excision
  • Carbon dioxide laser
  • Cauterizing scalpel (Shaw scalpel)
  • Combination

23
Agents reported (off-label) in rosacea
  • Oral ivermectin
  • Topical permethrin
  • Topical pimecrolimus
  • Photodynamic therapy (methyl ALA/red light)
  • Azithromycin
  • Oxymetazoline (a1 adrenergic agonist)

24
Managing Difficult Cases
25
Possible future treatments
  • Improved laser/light protocols
  • Agents for erythema
  • COL 118 (brimonidine)
  • Topical ivermectin
  • Topical dapsone
  • Agents targeting cathelicidin peptides/kallikrein
    protease inhibitors

26
Rosacea vs. acne
27
Rosacea/seborrheic dermatitis
28
Granulomatous Rosacea
29
Rosacea with solid facial edema
30
Two Types of Edema
  • Transient, post-flushing soft edema
  • Subtle
  • Variable
  • Over primarily inactive facial musculature
  • Long-lasting, hard, non-pitting
  • Solid facial edema

31
Rosacea fulminans/ pyoderma faciale
32
Ocular rosacea
33
Ocular Rosacea (Blepharitis)
  • Watery or bloodshot appearance
  • Foreign body sensation
  • Burning or stinging
  • Dryness
  • Itching
  • Light sensitivity
  • Blurred vision
  • Telangiectases of the conjunctiva and lid margin
  • Lid and periocular erythema
  • Blepharitis
  • Conjunctivitis
  • Irregularity of eyelid margins
  • Meibomian gland dysfunction
  • May occur before, with, or following cutaneous
    signs and symptoms

34
Ocular rosacea recommendations
  • Lid hygiene
  • Warm soaks
  • Removal of crusts (baby shampoo)
  • Artificial tears
  • Ophthalmic preparations
  • Cyclosporine (Restasis)

35
(No Transcript)
36
www.acnesociety.org
Write a Comment
User Comments (0)
About PowerShow.com